193 related articles for article (PubMed ID: 38451525)
1. P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Deployment of a Drug-Eluting Stent: The SHARE Randomized Clinical Trial.
Min PK; Kang TS; Cho YH; Cheong SS; Kim BK; Kwon SW; Park WJ; Lee JH; Kim W; Lee WS; Yoon YW; Lee BK; Kwon HM; Hong BK;
JAMA Netw Open; 2024 Mar; 7(3):e240877. PubMed ID: 38451525
[TBL] [Abstract][Full Text] [Related]
2. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial.
Hahn JY; Song YB; Oh JH; Chun WJ; Park YH; Jang WJ; Im ES; Jeong JO; Cho BR; Oh SK; Yun KH; Cho DK; Lee JY; Koh YY; Bae JW; Choi JW; Lee WS; Yoon HJ; Lee SU; Cho JH; Choi WG; Rha SW; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC;
JAMA; 2019 Jun; 321(24):2428-2437. PubMed ID: 31237645
[TBL] [Abstract][Full Text] [Related]
3. Long-term Effects of P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention: 3-Year Follow-up of the SMART-CHOICE Randomized Clinical Trial.
Choi KH; Park YH; Song YB; Park TK; Lee JM; Yang JH; Choi JH; Choi SH; Oh JH; Chun WJ; Jang WJ; Im ES; Jeong JO; Cho BR; Oh SK; Yun KH; Cho DK; Lee JY; Koh YY; Bae JW; Choi JW; Lee WS; Yoon HJ; Lee SU; Cho JH; Choi WG; Rha SW; Gwon HC; Hahn JY;
JAMA Cardiol; 2022 Nov; 7(11):1100-1108. PubMed ID: 36169938
[TBL] [Abstract][Full Text] [Related]
4. Comparison of 3- to 6-Month Versus 12-Month Dual Antiplatelet Therapy After Coronary Intervention Using the Contemporary Drug-Eluting Stents With Ultrathin Struts: The HOST-IDEA Randomized Clinical Trial.
Han JK; Hwang D; Yang S; Park SH; Kang J; Yang HM; Park KW; Kang HJ; Koo BK; Hur SH; Kim W; Kim SY; Park SH; Han SH; Kim SH; Shin S; Kim YH; Park K; Lee N; Lee SJ; Kim JW; Kim HS
Circulation; 2023 May; 147(18):1358-1368. PubMed ID: 36871230
[TBL] [Abstract][Full Text] [Related]
5. Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial.
Kim BK; Hong SJ; Cho YH; Yun KH; Kim YH; Suh Y; Cho JY; Her AY; Cho S; Jeon DW; Yoo SY; Cho DK; Hong BK; Kwon H; Ahn CM; Shin DH; Nam CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y;
JAMA; 2020 Jun; 323(23):2407-2416. PubMed ID: 32543684
[TBL] [Abstract][Full Text] [Related]
6. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial.
Watanabe H; Domei T; Morimoto T; Natsuaki M; Shiomi H; Toyota T; Ohya M; Suwa S; Takagi K; Nanasato M; Hata Y; Yagi M; Suematsu N; Yokomatsu T; Takamisawa I; Doi M; Noda T; Okayama H; Seino Y; Tada T; Sakamoto H; Hibi K; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Hanaoka KI; Morino Y; Kozuma K; Kadota K; Furukawa Y; Nakagawa Y; Kimura T;
JAMA; 2019 Jun; 321(24):2414-2427. PubMed ID: 31237644
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial.
Watanabe H; Morimoto T; Natsuaki M; Yamamoto K; Obayashi Y; Ogita M; Suwa S; Isawa T; Domei T; Yamaji K; Tatsushima S; Watanabe H; Ohya M; Tokuyama H; Tada T; Sakamoto H; Mori H; Suzuki H; Nishikura T; Wakabayashi K; Hibi K; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Morino Y; Kadota K; Furukawa Y; Nakagawa Y; Kimura T;
JAMA Cardiol; 2022 Apr; 7(4):407-417. PubMed ID: 35234821
[TBL] [Abstract][Full Text] [Related]
8. Extended Clopidogrel Monotherapy vs DAPT in Patients With Acute Coronary Syndromes at High Ischemic and Bleeding Risk: The OPT-BIRISK Randomized Clinical Trial.
Li Y; Li J; Wang B; Jing Q; Zeng Y; Hou A; Wang Z; Liu A; Zhang J; Zhang Y; Zhang P; Jiang D; Liu B; Fan J; Zhang J; Li L; Su G; Yang M; Jiang W; Qu P; Zeng H; Li L; Qiu M; Ru L; Chen S; Zhou Y; Qiao S; Stone GW; Angiolillo DJ; Han Y;
JAMA Cardiol; 2024 Jun; 9(6):523-531. PubMed ID: 38630489
[TBL] [Abstract][Full Text] [Related]
9. Rationale and design of the comparison between a P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing implantation of coronary drug-eluting stents (SMART-CHOICE): A prospective multicenter randomized trial.
Song YB; Oh SK; Oh JH; Im ES; Cho DK; Cho BR; Lee JY; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC; Hahn JY
Am Heart J; 2018 Mar; 197():77-84. PubMed ID: 29447787
[TBL] [Abstract][Full Text] [Related]
10. Sex-Based Outcomes of P2Y12 Inhibitor Monotherapy After Three Months of Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention.
Shin ES; Her AY; Kim B; Hahn JY; Song YB; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC;
J Korean Med Sci; 2023 Nov; 38(45):e383. PubMed ID: 37987108
[TBL] [Abstract][Full Text] [Related]
11. Stopping Aspirin Within 1 Month After Stenting for Ticagrelor Monotherapy in Acute Coronary Syndrome: The T-PASS Randomized Noninferiority Trial.
Hong SJ; Lee SJ; Suh Y; Yun KH; Kang TS; Shin S; Kwon SW; Lee JW; Cho DK; Park JK; Bae JW; Kang WC; Kim S; Lee YJ; Ahn CM; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Hong MK;
Circulation; 2024 Feb; 149(8):562-573. PubMed ID: 37878786
[TBL] [Abstract][Full Text] [Related]
12. Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials.
Giacoppo D; Matsuda Y; Fovino LN; D'Amico G; Gargiulo G; Byrne RA; Capodanno D; Valgimigli M; Mehran R; Tarantini G
Eur Heart J; 2021 Jan; 42(4):308-319. PubMed ID: 33284979
[TBL] [Abstract][Full Text] [Related]
13. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial.
Ge Z; Kan J; Gao X; Raza A; Zhang JJ; Mohydin BS; Gao F; Shao Y; Wang Y; Zeng H; Li F; Khan HS; Mengal N; Cong H; Wang M; Chen L; Wei Y; Chen F; Stone GW; Chen SL;
Lancet; 2024 May; 403(10439):1866-1878. PubMed ID: 38599220
[TBL] [Abstract][Full Text] [Related]
14. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Feres F; Costa RA; Abizaid A; Leon MB; Marin-Neto JA; Botelho RV; King SB; Negoita M; Liu M; de Paula JE; Mangione JA; Meireles GX; Castello HJ; Nicolela EL; Perin MA; Devito FS; Labrunie A; Salvadori D; Gusmão M; Staico R; Costa JR; de Castro JP; Abizaid AS; Bhatt DL;
JAMA; 2013 Dec; 310(23):2510-22. PubMed ID: 24177257
[TBL] [Abstract][Full Text] [Related]
15. Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug-Eluting Stent Implantation (OPTION): A Randomized, Open-Label, End Point-Blinded, Noninferiority Trial.
Wu H; Xu L; Zhao X; Zhang H; Cheng K; Wang X; Chen M; Li G; Huang J; Lan J; Wei G; Zhang C; Wang Y; Qian J; Ge J;
Circulation; 2023 Jan; 147(3):212-222. PubMed ID: 36335890
[TBL] [Abstract][Full Text] [Related]
16. Biodegradable-Polymer or Durable-Polymer Stents in Patients at High Bleeding Risk: A Randomized, Open-Label Clinical Trial.
Valgimigli M; Wlodarczak A; Tölg R; Merkely B; Kelbæk H; Legutko J; Galli S; Godin M; Toth GG; Lhermusier T; Honton B; Dietrich PL; Stammen F; Ferdinande B; Silvain J; Capodanno D; Cayla G;
Circulation; 2023 Sep; 148(13):989-999. PubMed ID: 37624364
[TBL] [Abstract][Full Text] [Related]
17. Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial.
Ge Z; Gao XF; Kan J; Kong XQ; Zuo GF; Ye F; Tian NL; Lin S; Liu ZZ; Shao YB; He YQ; Wen SY; Yang Q; Xia Y; Wang ZZ; Xiao PX; Li F; Zeng HS; Yang S; Wang Y; Tao L; Gao DS; Qu H; Qian XS; Han YL; Chen F; Zhang JJ; Chen SL
Am Heart J; 2021 Jun; 236():49-58. PubMed ID: 33621541
[TBL] [Abstract][Full Text] [Related]
18. 1-Year Safety of 3-Month Dual Antiplatelet Therapy Followed by Aspirin or P2Y
Kozuma K; Kinoshita Y; Hioki H; Nanasato M; Ito Y; Yamaguchi J; Shiode N; Hibi K; Tanabe K; Ako J; Morino Y; Hirohata A; Sonoda S; Nakagawa Y; Ikari Y;
Circ J; 2020 Dec; 85(1):19-26. PubMed ID: 33191392
[TBL] [Abstract][Full Text] [Related]
19. Bioabsorbable polymer drug-eluting stents with 4-month dual antiplatelet therapy versus durable polymer drug-eluting stents with 12-month dual antiplatelet therapy in patients with left main coronary artery disease: the IDEAL-LM randomised trial.
van Geuns RJ; Chun-Chin C; McEntegart MB; Merkulov E; Kretov E; Lesiak M; O'Kane P; Hanratty CG; Bressollette E; Silvestri M; Wlodarczak A; Barragan P; Anderson R; Protopopov A; Peace A; Menown I; Rocchiccioli P; Onuma Y; Oldroyd KG
EuroIntervention; 2022 Apr; 17(18):1467-1476. PubMed ID: 35285803
[TBL] [Abstract][Full Text] [Related]
20. 1-Month Dual-Antiplatelet Therapy Followed by Aspirin Monotherapy After Polymer-Free Drug-Coated Stent Implantation: One-Month DAPT Trial.
Hong SJ; Kim JS; Hong SJ; Lim DS; Lee SY; Yun KH; Park JK; Kang WC; Kim YH; Yoon HJ; Won H; Nam CM; Ahn CM; Kim BK; Ko YG; Choi D; Jang Y; Hong MK;
JACC Cardiovasc Interv; 2021 Aug; 14(16):1801-1811. PubMed ID: 34332946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
